Shingles vaccine put to the test in frail patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

3.1.1. Adult population (longitudinal study) General inclusion criteria Age ≥ 18 years Eligibility for RZV vaccination Written informed consent Inclusion criteria for specific sub-groups: Rheumatologic patients: * rheumatoid arthritis diagnosis according to classification criteria of 1987 and/or 2018 * eligibility or in therapy with JAKis o CTLA4-Ig (monotherapy or DMARD combination) Oncologic patients: * confirmed histological diagnosis of solid tumour (any type) * life expectancy ≥ 6 months * Patients with cancer who have to start immunotherapy with or without chemotherapy/targeted therapy Hematologic patients: * Patients with haematological malignancy treated with drugs (chemotherapy, new drugs, target therapies) other than antibodies. * Patients treated with anti-CD19 or CD20 or CD22 or CD30 or anti-PD1 antibodies with or without chemotherapy * Patients receiving autologous or allogeneic transplantation or CAR-T cells Neurologic patients: * Multiple sclerosis (MS) diagnosis according to McDonald criteria 2017 * Eligibility or in therapy with first- or second-line immunosuppressive treatments General Exclusion criteria No informed consent Previous HZ vaccination Documented reactions or allergies against vaccines Severe infections during the previous 3 months 3.1.2. Pediatric population (cross-sectional study) Inclusion criteria Written informed consent from parents legal tutor and child assent (depending on age) Serology for VZV positive Hematologic patients: * Patients with haematological malignancies treated with chemotherapy including experimental drugs and target therapies; * Patients with haematological malignancies undergoing B-cell depleting treatments, e.g. CAR-T cell therapy or anti-CD20, antiCD22, anti-CD30, anti-CD19 monoclonal or bispecific antibodies * Patients with haematological malignancies receiving allogeneic transplantation due to malignant or non-malignant diseases, including primary immunodeficiencies, hemoglobinopathies and acquired or inherited bone marrow failure syndrome. Rheumatologic patients: 1. patients with connective tissue diseases (including systemic lupus erythematosus, SLE, juvenile dermathomyositis, JDM, and scleroderma) treated with B cell depleting therapies (anti-CD20); 2. patients with juvenile idiopathic arthritis (JIA) treated with TNF inhibitors. The corresponding disease control populations will be patients with the same diseases listed above, who are not receiving anti-CD20 or TNF inhibitors, respectively.